MDA Awards $1 Million to Tivorsan Pharmaceuticals for Accelerating Pivotal Pre-Clinical Work on TVN-102 as a Potential Muscular Dystrophy Treatment

Rhode Island based biotech startup Tivorsan Pharmaceuticals has received $1 million from the Muscular Dystrophy Association’s Venture Philanthropy division to accelerate its pre-clinical research for TVN-102 for the treatment of Duchenne muscular dystrophy (DMD). The drug mimics a protein naturally found on muscle fiber membranes that stabilizes neuromuscular junctions, structures compromised in neuromuscular diseases like DMD and ALS.

Click here to read more.

Share this: